A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
This is a 48-week study to collect additional information on the safety, tolerability,
pharmacokinetics, and antiviral activity of an investigational regimen (course of therapy)
including FDA approved HIV drugs in HIV-infected patients 2 - 18 years old.